Premium
The development of peptide‐coated nanoparticles for targeting and drug delivery to cancer cells
Author(s) -
Poursharifi Mina,
dragulska Sylwia Anna,
Chen Ying,
Martignetti John,
Mieszawska Aneta
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.02042
Subject(s) - nanocarriers , plga , nanomedicine , drug delivery , drug , cancer cell , peptide , cancer , pharmacology , chemistry , cancer research , medicine , nanotechnology , nanoparticle , in vitro , biochemistry , materials science
Ovarian Cancer (OC) is a most lethal female malignancy worldwide, mostly due to the late‐stage diagnosis and high recurrence rate. Survival statistics remain stuck at ~30% for the past four decades highlighting the necessity to improve the early stage detection and therapeutic outcomes. Nanotherapy in OC may provide significant and unique benefits for drug efficacy as well as for reducing the therapeutically limiting adverse effects associated with current treatment regimens. Herein, we report a unique nanoparticle (NP)‐based platform of peptide‐stabilized poly (lactic‐co‐glycolic acid) (PLGA). The ultimate goal is NP‐mediated targeted delivery of anticancer therapy and contrast agents. Morphology and small size (~100 nm) of NPs provide them an ideal candidate for mechanistic studies. We present detailed imaging studies of NPs uptake by OC cells as well as NPs distribution within cellular organelles obtained with high resolution live cell imaging. The results show a preferential accumulation of NPs in mitochondria. In addition, the in vitro studies include the NP‐based delivery of anticancer agents, such as Pt(II) and mitochondria‐targeting lonidamine. This project demonstrates potential of peptide‐stabilized nanocarrier as an effective nanomedicine against cancer. The PLGA is FDA approved and the amino acids of the peptides have Generally Regarded as Safe (GRAS) status. The NP platform is completely biodegradable, and as we demonstrate biologically active.